What is the Optimal Treatment Duration of Immunotherapy for NSCLC?
Non-small cell lung cancer (NSCLC) is the most frequent type of lung cancer in the world. The majority of patients with NSCLC without driver alterations in the metastatic setting and, increasingly, in the advanced setting, are treated with immunotherapy (IO) targeting the programmed cell death prote...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2024-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2024.19.139 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|